9/120
0.4 / 5 stars
All 120 Win/Lose results shown below
PLRX Roast Me summary
PLIANT THERAPEUTICS, INC. (PLRX). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LosePLRX / S&P -9.52% / 15.20% |
LosePLRX / S&P PLRX unavailable / 15.00% |
LosePLRX / S&P PLRX unavailable / 50.40% |
| 2026-Q11/3 |
WinPLRX / S&P 3.28% / -4.33% |
LosePLRX / S&P PLRX unavailable / 11.30% |
LosePLRX / S&P PLRX unavailable / 27.70% |
| 2025-Q40/3 |
LosePLRX / S&P -17.57% / 2.65% |
LosePLRX / S&P PLRX unavailable / 9.00% |
LosePLRX / S&P PLRX unavailable / 13.40% |
| 2025-Q31/3 |
WinPLRX / S&P 27.59% / 8.12% |
LosePLRX / S&P PLRX unavailable / 4.61% |
LosePLRX / S&P PLRX unavailable / 13.45% |
| 2025-Q20/3 |
LosePLRX / S&P -14.07% / 10.94% |
LosePLRX / S&P PLRX unavailable / 4.83% |
LosePLRX / S&P PLRX unavailable / 10.63% |
| 2025-Q10/3 |
LosePLRX / S&P -89.75% / -4.27% |
LosePLRX / S&P PLRX unavailable / 4.98% |
LosePLRX / S&P PLRX unavailable / 10.57% |
| 2024-Q41/3 |
WinPLRX / S&P 17.48% / 2.41% |
LosePLRX / S&P -100.00% / 5.25% |
LosePLRX / S&P PLRX unavailable / 6.15% |
| 2024-Q30/3 |
LosePLRX / S&P 4.28% / 5.89% |
LosePLRX / S&P -100.00% / 5.89% |
LosePLRX / S&P PLRX unavailable / 6.11% |
| 2024-Q20/3 |
LosePLRX / S&P -27.85% / 4.28% |
LosePLRX / S&P -100.00% / 5.38% |
LosePLRX / S&P PLRX unavailable / 5.12% |
| 2024-Q10/3 |
LosePLRX / S&P -17.73% / 10.56% |
LosePLRX / S&P -97.46% / 5.71% |
LosePLRX / S&P PLRX unavailable / 5.59% |
| 2023-Q40/3 |
LosePLRX / S&P 4.44% / 11.69% |
LosePLRX / S&P -83.69% / 6.81% |
LosePLRX / S&P PLRX unavailable / 7.78% |
| 2023-Q30/3 |
LosePLRX / S&P -4.30% / -3.27% |
LosePLRX / S&P -63.53% / 7.52% |
LosePLRX / S&P PLRX unavailable / -5.03% |
| 2023-Q20/3 |
LosePLRX / S&P -31.88% / 8.74% |
LosePLRX / S&P -48.95% / 9.50% |
LosePLRX / S&P PLRX unavailable / -8.57% |
| 2023-Q12/3 |
WinPLRX / S&P 37.61% / 7.50% |
WinPLRX / S&P 46.95% / 10.77% |
LosePLRX / S&P PLRX unavailable / -15.69% |
| 2022-Q41/3 |
LosePLRX / S&P -7.47% / 7.56% |
WinPLRX / S&P 27.91% / 11.88% |
LosePLRX / S&P PLRX unavailable / -17.99% |
| 2022-Q31/3 |
WinPLRX / S&P 160.80% / -4.88% |
LosePLRX / S&P -3.18% / 13.47% |
LosePLRX / S&P PLRX unavailable / -1.41% |
| 2022-Q21/3 |
WinPLRX / S&P 14.27% / -16.10% |
LosePLRX / S&P -25.64% / 13.71% |
LosePLRX / S&P PLRX unavailable / 11.04% |
| 2022-Q10/3 |
LosePLRX / S&P -48.07% / -4.60% |
LosePLRX / S&P -55.84% / 15.97% |
LosePLRX / S&P PLRX unavailable / 42.23% |
| 2021-Q40/3 |
LosePLRX / S&P -20.02% / 11.03% |
LosePLRX / S&P -81.89% / 15.00% |
LosePLRX / S&P PLRX unavailable / 96.40% |
| 2021-Q30/3 |
LosePLRX / S&P -42.03% / 0.58% |
LosePLRX / S&P PLRX unavailable / 10.77% |
LosePLRX / S&P -110.94% / 69.42% |
| 2021-Q20/3 |
LosePLRX / S&P -25.96% / 8.55% |
LosePLRX / S&P PLRX unavailable / 6.58% |
LosePLRX / S&P -114.73% / 51.81% |
| 2021-Q11/3 |
WinPLRX / S&P 73.11% / 6.17% |
LosePLRX / S&P PLRX unavailable / -1.06% |
LosePLRX / S&P -147.83% / 7.39% |
| 2020-Q40/3 |
LosePLRX / S&P 0.31% / 12.15% |
LosePLRX / S&P -26.70% / -3.72% |
LosePLRX / S&P PLRX unavailable / -33.42% |
| 2020-Q30/3 |
LosePLRX / S&P -30.22% / 8.93% |
LosePLRX / S&P PLRX unavailable / -2.04% |
LosePLRX / S&P PLRX unavailable / -27.10% |
| 2020-Q20/3 |
LosePLRX / S&P PLRX unavailable / 20.54% |
LosePLRX / S&P PLRX unavailable / -0.46% |
LosePLRX / S&P PLRX unavailable / -27.11% |
| 2020-Q10/3 |
LosePLRX / S&P PLRX unavailable / -19.60% |
LosePLRX / S&P PLRX unavailable / 3.47% |
LosePLRX / S&P PLRX unavailable / -14.75% |
| 2019-Q40/3 |
LosePLRX / S&P PLRX unavailable / 9.07% |
LosePLRX / S&P PLRX unavailable / 5.36% |
LosePLRX / S&P PLRX unavailable / 2.99% |
| 2019-Q30/3 |
LosePLRX / S&P PLRX unavailable / 1.70% |
LosePLRX / S&P PLRX unavailable / 5.02% |
LosePLRX / S&P PLRX unavailable / 0.21% |
| 2019-Q20/3 |
LosePLRX / S&P PLRX unavailable / 4.30% |
LosePLRX / S&P PLRX unavailable / 6.64% |
LosePLRX / S&P PLRX unavailable / 8.65% |
| 2019-Q10/3 |
LosePLRX / S&P PLRX unavailable / 13.65% |
LosePLRX / S&P PLRX unavailable / 8.12% |
LosePLRX / S&P PLRX unavailable / 14.29% |
| 2018-Q40/3 |
LosePLRX / S&P PLRX unavailable / -13.52% |
LosePLRX / S&P PLRX unavailable / 9.05% |
LosePLRX / S&P PLRX unavailable / 18.23% |
| 2018-Q30/3 |
LosePLRX / S&P PLRX unavailable / 7.71% |
LosePLRX / S&P PLRX unavailable / 10.21% |
LosePLRX / S&P PLRX unavailable / 19.06% |
| 2018-Q20/3 |
LosePLRX / S&P PLRX unavailable / 3.43% |
LosePLRX / S&P PLRX unavailable / 9.03% |
LosePLRX / S&P PLRX unavailable / 14.46% |
| 2018-Q10/3 |
LosePLRX / S&P PLRX unavailable / -0.76% |
LosePLRX / S&P PLRX unavailable / 7.68% |
LosePLRX / S&P PLRX unavailable / 12.46% |
| 2017-Q40/3 |
LosePLRX / S&P PLRX unavailable / 6.64% |
LosePLRX / S&P PLRX unavailable / 7.03% |
LosePLRX / S&P PLRX unavailable / 13.82% |
| 2017-Q30/3 |
LosePLRX / S&P PLRX unavailable / 4.48% |
LosePLRX / S&P PLRX unavailable / 5.68% |
LosePLRX / S&P PLRX unavailable / 17.57% |
| 2017-Q20/3 |
LosePLRX / S&P PLRX unavailable / 3.09% |
LosePLRX / S&P PLRX unavailable / 4.83% |
LosePLRX / S&P PLRX unavailable / 17.74% |
| 2017-Q10/3 |
LosePLRX / S&P PLRX unavailable / 6.07% |
LosePLRX / S&P PLRX unavailable / 3.67% |
LosePLRX / S&P PLRX unavailable / 13.32% |
| 2016-Q40/3 |
LosePLRX / S&P PLRX unavailable / 3.82% |
LosePLRX / S&P PLRX unavailable / 2.09% |
LosePLRX / S&P PLRX unavailable / 7.05% |
| 2016-Q30/3 |
LosePLRX / S&P PLRX unavailable / 3.85% |
LosePLRX / S&P PLRX unavailable / 0.20% |
LosePLRX / S&P PLRX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | PLRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -32.32% | 20.78% |
| Annualized return | -32.32% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | PLRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -93.89% | 83.14% |
| Annualized return | -42.82% | 12.86% |
10Y · 2020-06-03 to 2026-08-28
| Metric | PLRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.79% | 319.30% |
| Annualized return | -25.58% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |